Generic Biotech Drugs Could Vault Industry to New Heights

By Chi, Judy | Drug Topics, June 1, 1996 | Go to article overview

Generic Biotech Drugs Could Vault Industry to New Heights


Chi, Judy, Drug Topics


If you think the generic drug industry has grown a lot lately, you ain't seen nothin' yet. There's still a lot more growth to come, promised Jerry Treppel, senior v.p. at Dillon, Read & Co., at a generic drug conference sponsored by his New York City equity research firm, which specializes in pharmaceuticals.

According to Treppel, a fresh development that could take this industry to new heights is generic biotech drugs. The patents for such blockbuster biotech drugs as EPO (Epogen, Amgen; Procrit, Ortho Biotech) : t-PA (alteplase, Activase, Genentech), the interleukins, and others will begin to expire around the start of the next decade. But this fact has not seeped into Wall Street's consciousness yet, he noted.

Producing bioequivalent copies of these injectable drugs is not a barrier, he believes. The technology is there, and facilities are now under construction for the purpose of manufacturing generic biotech drugs. "All one needs is fermentation capability, sterile manufacturing, and access to worldclass biotechnology brainpower. There are companies in this industry that possess those characteristics already," he said.

Another prediction the generic drug analyst made is that "the industry will wind up with user fees." User fees, which are fees drug companies pay to the Food & Drug Administration to speed the review of drug applications, would "alleviate the ANDA bottleneck now found at the Office of Generic Drugs," he explained.

Although some generic companies are opposed to user fees, Treppel contended that the sooner they are implemented, the better. The reason, he explained, is that the generic industry's customers are "increasingly narrowing down the number of suppliers they are willing to deal with." Any generic firm that can quickly expand its product line will have a leg up on its competition.

In Treppel's view, the U.S. generic industry will "consolidate to a few very large players, and the trend is already under way. By the end of this century, most of the larger generic companies will really be hybrids, both generic and brand, making their revenue and earnings stream much more predictable than today."

Taking stock of the industry, the executive said it has won some important fights this year. As examples, he cited the approval of generic albuterol metered-dose inhalers and sucralfate (Carafate, Hoechst Marion Roussel), drugs with difficult bioequivalence issues. …

The rest of this article is only available to active members of Questia

Already a member? Log in now.

Notes for this article

Add a new note
If you are trying to select text to create highlights or citations, remember that you must now click or tap on the first word, and then click or tap on the last word.
One moment ...
Default project is now your active project.
Project items

Items saved from this article

This article has been saved
Highlights (0)
Some of your highlights are legacy items.

Highlights saved before July 30, 2012 will not be displayed on their respective source pages.

You can easily re-create the highlights by opening the book page or article, selecting the text, and clicking “Highlight.”

Citations (0)
Some of your citations are legacy items.

Any citation created before July 30, 2012 will labeled as a “Cited page.” New citations will be saved as cited passages, pages or articles.

We also added the ability to view new citations from your projects or the book or article where you created them.

Notes (0)
Bookmarks (0)

You have no saved items from this article

Project items include:
  • Saved book/article
  • Highlights
  • Quotes/citations
  • Notes
  • Bookmarks
Notes
Cite this article

Cited article

Style
Citations are available only to our active members.
Buy instant access to cite pages or passages in MLA, APA and Chicago citation styles.

(Einhorn, 1992, p. 25)

(Einhorn 25)

1. Lois J. Einhorn, Abraham Lincoln, the Orator: Penetrating the Lincoln Legend (Westport, CT: Greenwood Press, 1992), 25, http://www.questia.com/read/27419298.

Cited article

Generic Biotech Drugs Could Vault Industry to New Heights
Settings

Settings

Typeface
Text size Smaller Larger Reset View mode
Search within

Search within this article

Look up

Look up a word

  • Dictionary
  • Thesaurus
Please submit a word or phrase above.
Print this page

Print this page

Why can't I print more than one page at a time?

Help
Full screen

matching results for page

    Questia reader help

    How to highlight and cite specific passages

    1. Click or tap the first word you want to select.
    2. Click or tap the last word you want to select, and you’ll see everything in between get selected.
    3. You’ll then get a menu of options like creating a highlight or a citation from that passage of text.

    OK, got it!

    Cited passage

    Style
    Citations are available only to our active members.
    Buy instant access to cite pages or passages in MLA, APA and Chicago citation styles.

    "Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences." (Einhorn, 1992, p. 25).

    "Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences." (Einhorn 25)

    "Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences."1

    1. Lois J. Einhorn, Abraham Lincoln, the Orator: Penetrating the Lincoln Legend (Westport, CT: Greenwood Press, 1992), 25, http://www.questia.com/read/27419298.

    Cited passage

    Thanks for trying Questia!

    Please continue trying out our research tools, but please note, full functionality is available only to our active members.

    Your work will be lost once you leave this Web page.

    Buy instant access to save your work.

    Already a member? Log in now.

    Author Advanced search

    Oops!

    An unknown error has occurred. Please click the button below to reload the page. If the problem persists, please try again in a little while.